drugset / Trial / NCT02868892
A Study of Pemetrexed in Recurrent Cervical Adenocarcinomas
NaSingle-groupOpen-labelTreatment
Summary
Patients with advanced or recurrent adenocarcinoma or adenosquamous cell carcinoma of the cervix will receive Pemetrexed.
Timeline
- Start
- 2015-07
- Primary completion
- 2017-07
- Completion
- 2017-07
Outcome
Outcome not reported
Stopped: “departure of PI from institution and poor population for study participation”
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Pemetrexed | Small molecule | 500 mg/m2 | Intravenous |